Mersana Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRSN research report →
About the company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma.
- CEO
- Martin H. Huber
- IPO
- 2017
- Employees
- 102
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $145.36M
- P/E
- -2.06
- P/S
- 4.38
- P/B
- -2.44
- EV/EBITDA
- -1.38
- Div Yield
- 0.00%
- Gross Margin
- 99.14%
- Op Margin
- -203.06%
- Net Margin
- -211.21%
- ROE
- 183.15%
- ROIC
- -310.35%
- Revenue
- $40.50M · 9.88%
- Net Income
- $-69,192,000 · 59.69%
- EPS
- $-14.12 · 61.80%
- Op Income
- $-73,336,000
- FCF YoY
- 51.78%
- 52W High
- $30.39
- 52W Low
- $5.21
- 50D MA
- $22.88
- 200D MA
- $11.99
- Beta
- 0.43
- Avg Volume
- 135.97K
Get TickerSpark's AI analysis on MRSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,460 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,000 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 368 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,800 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,088 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 734 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 2,200 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 1,002 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 400 |
| Jan 6, 26 | Hack Andrew A. F. | sell | 118 |
Our MRSN coverage
Recent articles, reports, and earnings notes.
No research on MRSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MRSN report →Similar companies
Peers in the same neighborhood.